Soros Capital Management LLC Boosts Holdings in Danaher Corporation $DHR

Key Points

• Soros Capital Management LLC increased its stake in Danaher Corporation by 288.1%, holding a total of 12,991 shares valued at $2.66 million.
• Multiple hedge funds, including Vanguard Group Inc. and Price T Rowe Associates Inc., have also increased their holdings in Danaher, with institutional investors currently owning 79.05% of the stock.
• Danaher recently reported quarterly earnings of $1.80 EPS, exceeding the consensus estimate of $1.64, while also forecasting annual EPS guidance of $7.63 for the fiscal year.

Soros Capital Management LLC grew its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 288.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,991 shares of the conglomerate's stock after purchasing an additional 9,644 shares during the quarter. Soros Capital Management LLC's holdings in Danaher were worth $2,663,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in DHR. FAS Wealth Partners Inc. boosted its position in Danaher by 20.6% during the 4th quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock worth $2,203,000 after buying an additional 1,639 shares during the period. MGO One Seven LLC raised its stake in shares of Danaher by 485.7% during the first quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock valued at $5,145,000 after acquiring an additional 20,813 shares during the last quarter. Asahi Life Asset Management CO. LTD. acquired a new position in shares of Danaher during the first quarter worth $539,000. Horizon Financial Services LLC grew its stake in shares of Danaher by 20,400.0% in the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock worth $1,681,000 after purchasing an additional 8,160 shares during the last quarter. Finally, EFG Asset Management Americas Corp. grew its stake in shares of Danaher by 13.1% in the first quarter. EFG Asset Management Americas Corp. now owns 36,080 shares of the conglomerate's stock worth $7,396,000 after purchasing an additional 4,191 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Up 0.2%

Danaher stock traded up $0.42 during mid-day trading on Thursday, reaching $205.42. The stock had a trading volume of 2,519,853 shares, compared to its average volume of 3,496,339. The firm has a market capitalization of $147.09 billion, a PE ratio of 27.22, a price-to-earnings-growth ratio of 2.86 and a beta of 0.73. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.90. The stock's 50-day simple moving average is $201.23 and its 200-day simple moving average is $199.46. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter last year, the firm earned $1.72 EPS. The firm's revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 11.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Wells Fargo & Company lowered their target price on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 23rd. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a research report on Friday, July 11th. Deutsche Bank Aktiengesellschaft cut their price objective on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Evercore ISI decreased their target price on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Finally, Barclays restated an "overweight" rating and set a $225.00 price target (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $247.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.